Polaris Group (TPE:6550)

Market Cap	23.88B -32.2%
Revenue (ttm)	70.83M -6.4%
Net Income	-3.01B
EPS	-3.93
Shares Out	770.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	939,005
Average Volume	1,231,077
Open	30.55
Previous Close	31.00
Day's Range	30.55 - 31.45
52-Week Range	26.35 - 52.00
Beta	0.16
RSI	48.36
Earnings Date	Mar 13, 2026

About Polaris Group

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Grand Cayman.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 165
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6550

Financial Performance

In 2024, Polaris Group's revenue was 107.00 million, an increase of 1330.29% compared to the previous year's 7.48 million. Losses were -2.50 billion, 67.7% more than in 2023.